FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Hooper

Research Profile

Chemicals & Drugs

Procedures

Microbial Sensitivity Tests

Living Beings

Physiology

Concepts & Ideas

Molecular Sequence Data

Co-author Network

Publications

TOP 3
George A Jacoby; David C Hooper
Phylogenetic analysis of chromosomally determined qnr and related proteins.
Erica S Shenoy; David C Hooper; Heather Hsu; Farzad Noubary; Rochelle P Walensky
National survey of infection preventionists: policies for discontinuation of contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus.
Yanpeng Ding; Yingmei Fu; Jean C Lee; David C Hooper
Staphylococcus aureus NorD, a putative efflux pump coregulated with the Opp1 oligopeptide permease, contributes selectively to fitness in vivo.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Hooper (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: George A Jacoby; David C Hooper
Phylogenetic analysis of chromosomally determined qnr and related proteins.
Antimicrobial agents and chemotherapy 2013;57(4):1930-4.
2012: Erica S Shenoy; David C Hooper; Heather Hsu; Farzad Noubary; Rochelle P Walensky
National survey of infection preventionists: policies for discontinuation of contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2012;33(12):1272-5.
2012: Yanpeng Ding; Yingmei Fu; Jean C Lee; David C Hooper
Staphylococcus aureus NorD, a putative efflux pump coregulated with the Opp1 oligopeptide permease, contributes selectively to fitness in vivo.
Journal of bacteriology 2012;194(23):6586-93.
2012: Erica S Shenoy; Rochelle P Walensky; Hang Lee; Benjamin Orcutt; David C Hooper
Resource burden associated with contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: the patient access managers' perspective.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2012;33(8):849-52.
2012: Isaac I Bogoch; Benjamin T Davis; David C Hooper
Severe babesiosis in a patient treated with a tumor necrosis factor α antagonist.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012;54(8):1215-6.
2012: Que Chi Truong-Bolduc; Regis Villet; Gilles R Bolduc; Zoe Estabrooks; Liao Chun Hsing; G Florent Taguezem; David C Hooper
Reduced aeration affects the expression of the NorB efflux pump of Staphylococcus aureus by posttranslational modification of MgrA.
Journal of bacteriology 2012;194(7):1823-34.
2011: Ryo Okumura; Mariah Gavin; George Jacoby; Chun-Hsing Liao; David C Hooper
Quinolone induction of qnrVS1 in Vibrio splendidus and plasmid-carried qnrS1 in Escherichia coli, a mechanism independent of the SOS system.
Antimicrobial agents and chemotherapy 2011;55(12):5942-5.
2011: Que Chi Truong-Bolduc; Paul Dunman; T Eidem; David C Hooper
Transcriptional profiling analysis of the global regulator NorG, a GntR-like protein of Staphylococcus aureus.
Journal of bacteriology 2011;193(22):6207-14.
2011: George Jacoby; Caitlin M Griffin; David C Hooper
Citrobacter spp. as a source of qnrB Alleles.
Antimicrobial agents and chemotherapy 2011;55(11):4979-84.
2011: Que Chi Truong-Bolduc; Chun-Hsing Liao; Ryo Okumura; Jennifer Bevis; Gilles R Bolduc; Brian Celino; David C Hooper
Implication of the NorB efflux pump in the adaptation of Staphylococcus aureus to growth at acid pH and in resistance to moxifloxacin.
Antimicrobial agents and chemotherapy 2011;55(7):3214-9.
2011: Hong Bin Kim; Chi Hye Park; Mariah Gavin; George A Jacoby; David C Hooper
Cold shock induces qnrA expression in Shewanella algae.
Antimicrobial agents and chemotherapy 2011;55(1):414-6.
2010: E P Hyle; M J Ferraro; M Silver; H Lee; David C Hooper
Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2010;31(12):1242-9.
2010: Anton Y Peleg; David C Hooper
Hospital-acquired infections due to gram-negative bacteria.
The New England journal of medicine 2010;362(19):1804-13.
2010: Que Chi Truong-Bolduc; David C Hooper
Phosphorylation of MgrA and its effect on expression of the NorA and NorB efflux pumps of Staphylococcus aureus.
Journal of bacteriology 2010;192(10):2525-34.
2009: Jacob Strahilevitz; George A Jacoby; David C Hooper; Ari Robicsek
Plasmid-mediated quinolone resistance: a multifaceted threat.
Clinical microbiology reviews 2009;22(4):664-89.
2009: Minghua Wang; Qinglan Guo; Xiaogang Xu; Xiaoying Wang; Xinyu Ye; Shi Wu; David C Hooper; Minggui Wang
New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.
Antimicrobial agents and chemotherapy 2009;53(5):1892-7.
2009: Minghua Wang; George Jacoby; Debra M Mills; David C Hooper
SOS regulation of qnrB expression.
Antimicrobial agents and chemotherapy 2009;53(2):821-3.
2008: Que Chi Truong-Bolduc; Yanpeng Ding; David C Hooper
Posttranslational modification influences the effects of MgrA on norA expression in Staphylococcus aureus.
Journal of bacteriology 2008;190(22):7375-81.
2008: Yanpeng Ding; Yoshikuni Onodera; Jean C Lee; David C Hooper
NorB, an efflux pump in Staphylococcus aureus strain MW2, contributes to bacterial fitness in abscesses.
Journal of bacteriology 2008;190(21):7123-9.
2007: Que Chi Truong-Bolduc; David C Hooper
The transcriptional regulators NorG and MgrA modulate resistance to both quinolones and beta-lactams in Staphylococcus aureus.
Journal of bacteriology 2007;189(8):2996-3005.
2006: Chi Hye Park; Ari Robicsek; George Jacoby; Daniel F Sahm; David C Hooper
Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme.
Antimicrobial agents and chemotherapy 2006;50(11):3953-5.
2006: Ari Robicsek; George Jacoby; David C Hooper
The worldwide emergence of plasmid-mediated quinolone resistance.
The Lancet infectious diseases 2006;6(10):629-40.
2006: Ari Robicsek; Jacob Strahilevitz; Daniel F Sahm; George Jacoby; David C Hooper
qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States.
Antimicrobial agents and chemotherapy 2006;50(8):2872-4.
2006: Kathryn Gay; Ari Robicsek; Jacob Strahilevitz; Chi Hye Park; George Jacoby; Timothy J Barrett; Felicita Medalla; Tom M Chiller; David C Hooper
Plasmid-mediated quinolone resistance in non-Typhi serotypes of Salmonella enterica.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(3):297-304.
2006: Jacob Strahilevitz; Yoshikuni Onodera; David C Hooper
An improved expression plasmid for affinity purification of Staphylococcus aureus gyrase A subunit.
Protein expression and purification 2006;47(1):10-5.
2006: George Jacoby; Kelley E Walsh; Debra M Mills; Victoria J Walker; Herin Oh; Ari Robicsek; David C Hooper
qnrB, another plasmid-mediated gene for quinolone resistance.
Antimicrobial agents and chemotherapy 2006;50(4):1178-82.
2006: Que Chi Truong-Bolduc; Jacob Strahilevitz; David C Hooper
NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2006;50(3):1104-7.
2006: Jacob Strahilevitz; Ari Robicsek; David C Hooper
Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Antimicrobial agents and chemotherapy 2006;50(2):600-6.
2006: Ari Robicsek; Jacob Strahilevitz; George Jacoby; Mark J Macielag; Darren Abbanat; Chi Hye Park; Karen Bush; David C Hooper
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase.
Nature medicine 2006;12(1):83-8.
2005: Jacob Strahilevitz; Que Chi Truong-Bolduc; David C Hooper
DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.
Antimicrobial agents and chemotherapy 2005;49(12):5051-7.
2005: Noël de Souza; Shrikant V Gupte; Prasad K Deshpande; Vijaya N Desai; Satish B Bhawsar; Ravindra Yeole; Milind C Shukla; Jacob Strahilevitz; David C Hooper; Bülent Bozdogan; Peter C Appelbaum; Michael R Jacobs; Nitin Shetty; Mahesh V Patel; Rasendrakumar Jha; Habil F Khorakiwala
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Journal of medicinal chemistry 2005;48(16):5232-42.
2005: John H Tran; George Jacoby; David C Hooper
Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV.
Antimicrobial agents and chemotherapy 2005;49(7):3050-2.
2005: Ari Robicsek; Daniel F Sahm; Jacob Strahilevitz; George Jacoby; David C Hooper
Broader distribution of plasmid-mediated quinolone resistance in the United States.
Antimicrobial agents and chemotherapy 2005;49(7):3001-3.
2005: David C Hooper
Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40(12):1811-7.
2005: Jacob Strahilevitz; David C Hooper
Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Antimicrobial agents and chemotherapy 2005;49(5):1949-56.
2005: Que Chi Truong-Bolduc; Paul Dunman; Jacob Strahilevitz; Steven Projan; David C Hooper
MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus.
Journal of bacteriology 2005;187(7):2395-405.
2005: John H Tran; George Jacoby; David C Hooper
Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase.
Antimicrobial agents and chemotherapy 2005;49(1):118-25.
2004: Minggui Wang; Daniel F Sahm; George Jacoby; Yingyuan Zhang; David C Hooper
Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr.
Antimicrobial agents and chemotherapy 2004;48(4):1400-1.
2004: Minggui Wang; Daniel F Sahm; George Jacoby; David C Hooper
Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States.
Antimicrobial agents and chemotherapy 2004;48(4):1295-9.
2003: Dilek Ince; David C Hooper
Quinolone resistance due to reduced target enzyme expression.
Journal of bacteriology 2003;185(23):6883-92.
2003: Minggui Wang; John H Tran; George Jacoby; Yingyuan Zhang; Fu Wang; David C Hooper
Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China.
Antimicrobial agents and chemotherapy 2003;47(7):2242-8.
2003: Que Chi Truong-Bolduc; Xiamei Zhang; David C Hooper
Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus.
Journal of bacteriology 2003;185(10):3127-38.
2003: Dilek Ince; Xiamei Zhang; David C Hooper
Activity of and resistance to moxifloxacin in Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2003;47(4):1410-5.
2003: Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2003;47(1):274-82.
2002: Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
Antimicrobial agents and chemotherapy 2002;46(11):3370-80.
2002: David C Hooper
Fluoroquinolone resistance among Gram-positive cocci.
The Lancet infectious diseases 2002;2(9):530-8.
2002: Jian-Lin Yu; Leo Grinius; David C Hooper
NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes.
Journal of bacteriology 2002;184(5):1370-7.
2001: Dilek Ince; David C Hooper
Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2001;45(10):2755-64.
2001: David C Hooper
Minimizing potential resistance: the molecular view--a comment on Courvalin and Trieu-Cuot.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33 Suppl 3():S157-60.
2001: B Fournier; Que Chi Truong-Bolduc; Xiamei Zhang; David C Hooper
A mutation in the 5' untranslated region increases stability of norA mRNA, encoding a multidrug resistance transporter of Staphylococcus aureus.
Journal of bacteriology 2001;183(7):2367-71.
2001: David C Hooper
Mechanisms of action of antimicrobials: focus on fluoroquinolones.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32 Suppl 1():S9-S15.
2000: Dilek Ince; David C Hooper
Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.
Antimicrobial agents and chemotherapy 2000;44(12):3344-50.
2000: David C Hooper
Mechanisms of action and resistance of older and newer fluoroquinolones.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31 Suppl 2():S24-8.
2000: B Fournier; X Zhao; T Lu; K Drlica; David C Hooper
Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.
Antimicrobial agents and chemotherapy 2000;44(8):2160-5.
2000: B Fournier; David C Hooper
A new two-component regulatory system involved in adhesion, autolysis, and extracellular proteolytic activity of Staphylococcus aureus.
Journal of bacteriology 2000;182(14):3955-64.
2000: David C Hooper
New uses for new and old quinolones and the challenge of resistance.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;30(2):243-54.
2000: B Fournier; R Aras; David C Hooper
Expression of the multidrug resistance transporter NorA from Staphylococcus aureus is modified by a two-component regulatory system.
Journal of bacteriology 2000;182(3):664-71.
2000: David C Hooper
The fluoroquinolones after ciprofloxacin and ofloxacin.
Current clinical topics in infectious diseases 2000;20():63-91.
1999: David C Hooper
Mode of action of fluoroquinolones.
Drugs 1999;58 Suppl 2():6-10.
1998: David C Hooper
Clinical applications of quinolones.
Biochimica et biophysica acta 1998;1400(1-3):45-61.
1998: David C Hooper
Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27 Suppl 1():S54-63.
1998: B Fournier; David C Hooper
Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity.
Antimicrobial agents and chemotherapy 1998;42(8):2109-12.
1998: D P Kontoyiannis; K Ruoff; David C Hooper
Nocardia bacteremia. Report of 4 cases and review of the literature.
Medicine 1998;77(4):255-67.
1998: Scott K Fridkin; D S Yokoe; C G Whitney; A Onderdonk; David C Hooper
Epidemiology of a dominant clonal strain of vancomycin-resistant Enterococcus faecium at separate hospitals in Boston, Massachusetts.
Journal of clinical microbiology 1998;36(4):965-70.
1998: DA Pegues; C Colby; Patricia L Hibberd; L G Cohen; F M Ausubel; Stephen B Calderwood; David C Hooper
The epidemiology of resistance to ofloxacin and oxacillin among clinical coagulase-negative staphylococcal isolates: analysis of risk factors and strain types.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;26(1):72-9.
1998: B Fournier; David C Hooper
Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
Antimicrobial agents and chemotherapy 1998;42(1):121-8.
1997: DA Pegues; C F Pegues; Patricia L Hibberd; D S Ford; David C Hooper
Emergence and dissemination of a highly vancomycin-resistant vanA strain of Enterococcus faecium at a large teaching hospital.
Journal of clinical microbiology 1997;35(6):1565-70.
1997: S C Threlkeld; David C Hooper
Update on management of patients with Nocardia infection.
Current clinical topics in infectious diseases 1997;17():1-23.
1997: D M Breines; S Ouabdesselam; E Y Ng; Jacques Tankovic; S Shah; Claude-James Soussy; David C Hooper
Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV.
Antimicrobial agents and chemotherapy 1997;41(1):175-9.
1996: E Y Ng; Michele Trucksis; David C Hooper
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Antimicrobial agents and chemotherapy 1996;40(8):1881-8.
1995: Q C Truong; S Ouabdesselam; David C Hooper; Nicole Moreau; Claude-James Soussy
Sequential mutations of gyrA in Escherichia coli associated with quinolone therapy.
The Journal of antimicrobial chemotherapy 1995;36(6):1055-9.
1995: S Ouabdesselam; David C Hooper; Jacques Tankovic; Claude-James Soussy
Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations.
Antimicrobial agents and chemotherapy 1995;39(8):1667-70.
1995: David C Hooper
From fluoroquinolones to 2-pyridones.
Lancet 1995;345(8959):1192-3.
1995: David C Hooper
Quinolone mode of action.
Drugs 1995;49 Suppl 2():10-5.
1994: E Y Ng; Michele Trucksis; David C Hooper
Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome.
Antimicrobial agents and chemotherapy 1994;38(6):1345-55.
1993: Claude-James Soussy; J S Wolfson; E Y Ng; David C Hooper
Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus.
Antimicrobial agents and chemotherapy 1993;37(12):2588-92.
1993: David C Hooper
Quinolone mode of action--new aspects.
Drugs 1993;45 Suppl 3():8-14.
1992: David C Hooper; J S Wolfson; M A Bozza; E Y Ng
Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB.
Antimicrobial agents and chemotherapy 1992;36(5):1151-4.
1991: J S Wolfson; David C Hooper
Overview of fluoroquinolone safety.
The American journal of medicine 1991;91(6A):153S-161S.
1991: Michele Trucksis; J S Wolfson; David C Hooper
A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus.
Journal of bacteriology 1991;173(18):5854-60.
1991: J S Wolfson; David C Hooper
Pharmacokinetics of quinolones: newer aspects.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1991;10(4):267-74.
1991: Michele Trucksis; David C Hooper; J S Wolfson
Emerging resistance to fluoroquinolones in staphylococci: an alert.
Annals of internal medicine 1991;114(5):424-6.
1991: David C Hooper; J S Wolfson
Fluoroquinolone antimicrobial agents.
The New England journal of medicine 1991;324(6):384-94.
1990: J S Wolfson; David C Hooper; G L McHugh; M A Bozza; M N Swartz
Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents.
Antimicrobial agents and chemotherapy 1990;34(10):1938-43.
1989: J S Wolfson; David C Hooper
Comparative pharmacokinetics of ofloxacin and ciprofloxacin.
The American journal of medicine 1989;87(6C):31S-36S.
1989: David C Hooper; J S Wolfson
Bacterial resistance to the quinolone antimicrobial agents.
The American journal of medicine 1989;87(6C):17S-23S.
1989: David C Hooper; J S Wolfson
Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.
Antimicrobial agents and chemotherapy 1989;33(10):1662-7.
1989: J S Wolfson; David C Hooper
Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.
Antimicrobial agents and chemotherapy 1989;33(10):1655-61.
1989: J S Wolfson; David C Hooper
Fluoroquinolone antimicrobial agents.
Clinical microbiology reviews 1989;2(4):378-424.
1989: S P Cohen; Laura M McMurry; David C Hooper; J S Wolfson; Stuart B Levy
Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.
Antimicrobial agents and chemotherapy 1989;33(8):1318-25.
1989: J S Wolfson; David C Hooper
Bacterial resistance to quinolones: mechanisms and clinical importance.
Reviews of infectious diseases 1989;11 Suppl 5():S960-8.
1989: David C Hooper; J S Wolfson
Mode of action of the quinolone antimicrobial agents: review of recent information.
Reviews of infectious diseases 1989;11 Suppl 5():S902-11.
1989: J S Wolfson; David C Hooper; D J Shih; G L McHugh; M N Swartz
Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones.
Antimicrobial agents and chemotherapy 1989;33(5):705-9.
1989: David C Hooper; J S Wolfson; C Tung; K S Souza; M N Swartz
Effects of inhibition of the B subunit of DNA gyrase on conjugation in Escherichia coli.
Journal of bacteriology 1989;171(4):2235-7.
1989: David C Hooper; J S Wolfson; K S Souza; E Y Ng; G L McHugh; M N Swartz
Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.
Antimicrobial agents and chemotherapy 1989;33(3):283-90.
1989: R L Kerschmann; J S Wolfson; G L McHugh; G R Dickersin; David C Hooper; M N Swartz
Novobiocin-induced ultrastructural changes and antagonism of DNA synthesis in Trypanosoma cruzi amastigotes growing in cell-free medium.
The Journal of protozoology 1989;36(1):14-20.
1988: S P Cohen; David C Hooper; J S Wolfson; K S Souza; Laura M McMurry; Stuart B Levy
Endogenous active efflux of norfloxacin in susceptible Escherichia coli.
Antimicrobial agents and chemotherapy 1988;32(8):1187-91.
1988: J S Wolfson; David C Hooper
Norfloxacin: a new targeted fluoroquinolone antimicrobial agent.
Annals of internal medicine 1988;108(2):238-51.
1988: David C Hooper; J S Wolfson
Mode of action of the quinolone antimicrobial agents.
Reviews of infectious diseases 1988;10 Suppl 1():S14-21.
1987: J S Wolfson; David C Hooper; E Y Ng; K S Souza; G L McHugh; M N Swartz
Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers.
Antimicrobial agents and chemotherapy 1987;31(11):1861-3.
1987: J S Wolfson; G L McHugh; M N Swartz; E Y Ng; David C Hooper
Visualization of the mitochondrion-kinetoplast in viable Trypanosoma cruzi with rhodamine 123.
The Journal of parasitology 1987;73(4):866-9.
1987: David C Hooper; J S Wolfson; E Y Ng; M N Swartz
Mechanisms of action of and resistance to ciprofloxacin.
The American journal of medicine 1987;82(4A):12-20.
1986: David C Hooper; J S Wolfson; K S Souza; C Tung; G L McHugh; M N Swartz
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.
Antimicrobial agents and chemotherapy 1986;29(4):639-44.
1984: David C Hooper; J S Wolfson; G L McHugh; M D Swartz; C Tung; M N Swartz
Elimination of plasmid pMG110 from Escherichia coli by novobiocin and other inhibitors of DNA gyrase.
Antimicrobial agents and chemotherapy 1984;25(5):586-90.
1983: J S Wolfson; David C Hooper; M N Swartz; M D Swartz; G L McHugh
Novobiocin-induced elimination of F'lac and mini-F plasmids from Escherichia coli.
Journal of bacteriology 1983;156(3):1165-70.
1983: J S Wolfson; David C Hooper; M N Swartz; M D Swartz; G L McHugh
Rapid method for screening large numbers of Escherichia coli colonies for production of plasmid-mediated beta-lactamases.
Antimicrobial agents and chemotherapy 1983;23(2):308-12.
1982: David C Hooper; J S Wolfson; G L McHugh; M B Winters; M N Swartz
Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth.
Antimicrobial agents and chemotherapy 1982;22(4):662-71.
1982: J S Wolfson; David C Hooper; M N Swartz; G L McHugh
Antagonism of the B subunit of DNA gyrase eliminates plasmids pBR322 and pMG110 from Escherichia coli.
Journal of bacteriology 1982;152(1):338-44.